Risk of osteoporosis in patients with atrial fibrillation with and without oral anticoagulant therapy

References

• Lau WCY, Cheung CL, and Man KKC, et al. Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study. Ann Intern Med. 2020 Jul 7;173(1):1–9.
   Google Scholar
• Huang HK, Liu PP, Hsu JY, et al. Risk of osteoporosis in patients with atrial fibrillation using non-vitamin k antagonist oral anticoagulants or warfarin. J Am Heart Assoc. 2020 Jan 21;9(2):e013845.
   Google Scholar
• Lutsey PL, Norby FL, Ensrud KE, et al. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation. JAMA Intern Med. 2020 Feb 1;180(2):245–253.
   Google Scholar
• Hirsh J, Wood AJJ, Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991 Jun 27;324(26):1865–1875.
   Google Scholar
• Lian JB, Gundberg CM. Osteocalcin. Biochemical considerations and clinical applications. Clin Orthop Relat Res. 1988;226:267–291.
   Google Scholar
• Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41–57.
   Google Scholar
• Sparkenbaugh EM, Chantrathammachart P, Mickelson J, et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood. 2014 Mar 13;123(11):1747–1756.
   Google Scholar
• Loi F, Córdova LA, Pajarinen J, et al. Inflammation, fracture and bone repair. Bone. 2016 May;86:119–130.
   Google Scholar
• Signorelli SS, Scuto S, Marino E, et al. Anticoagulants and Osteoporosis. Int J Mol Sci. 2019 Oct 24;20(21):5275.
   Google Scholar
• Gage BF, Birman-Deych E, Radford MJ, et al. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med. 2006 Jan 23;166(2):241–246.
   Google Scholar
• Busingye D, Gianacas C, and Pollack A, et al. Data Resource Profile: medicineInsight, an Australian national primary health care database. Int J Epidemiol. 2019 Dec 1;48(6):1741–1741h.
   Google Scholar
• MedicineInsight. MedicineInsight Data Book and Data Dictionary. Sydney: NPS MedicineWise; 2021.
   Google Scholar
• Bezabhe WM, Bereznicki LR, Radford J, et al. Ten-year trends in the use of oral anticoagulants in Australian general practice patients with atrial fibrillation. Front Pharmacol. 2021;12:586370.
   Google Scholar
• Havard A, Manski-Nankervis JA, Thistlethwaite J, et al. Validity of algorithms for identifying five chronic conditions in MedicineInsight, an Australian national general practice database. BMC Health Serv Res. 2021 Jun 5;21(1):551.
   Google Scholar
• Bezabhe WM, Bereznicki LR, Radford J, et al. Oral anticoagulant treatment and the risk of dementia in patients with atrial fibrillation: a population-based cohort study. J Am Heart Assoc. 2022 Mar;18:e023098.
   Google Scholar
• Drug Utilisation Sub-Committee (DUSC). Novel oral anticoagulant: predicted vs actual analysis. Canberra: Australia Australian Government, Department of Health; 2016 June.
   Google Scholar
• Nguyen KD, Bagheri B, Bagheri H. Drug-induced bone loss: a major safety concern in Europe. Expert Opin Drug Saf. 2018 Oct;17(10):1005–1014.
   Google Scholar
• Wysham KD, Baker JF, Shoback DM. Osteoporosis and fractures in rheumatoid arthritis. Curr Opin Rheumatol. 2021 May 1;33(3):270–276.
   Google Scholar
• Chen YW, Ramsook AH, Coxson HO, et al. Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: a Systematic Review and Meta-analysis. Chest. 2019 Dec;156(6):1092–1110.
   Google Scholar
• Haarhaus M, Evenepoel P. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int. 2021 Sep;100(3):546–558.
   Google Scholar
• Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg. 2007 ;134(5):1128–1135.e3.
   Google Scholar
• Hughes RA, Heron J, Sterne JAC, et al. Accounting for missing data in statistical analyses: multiple imputation is not always the answer. Int J Epidemiol. 2019 Aug 1;48(4):1294–1304.
   Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014 Dec;12(12):1495–1499.
   Google Scholar
• Somjen D, Katzburg S, Gigi R, et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol. 2013 May;135:67–70.
   Google Scholar
• Solayar GN, Walsh PM, Mulhall KJ. The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet Disord. 2011 Oct 28;12:247.
   Google Scholar
• Rocha AL, Bighetti-Trevisan RL, Duffles LF, et al. Inhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblasts. Thromb Res. 2020 Feb;186:45–53.
   Google Scholar
• Yokoyama S, Ieda S, Nagano M, et al. Association between oral anticoagulants and osteoporosis: real-world data mining using a multi-methodological approach. Int J Med Sci. 2020;17(4):471–479.
   Google Scholar
• The Royal Australian College of General Practitioners. Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age 2017. [cited 2021 Dec 20]. Available from: https://www.racgp.org.au/getattachment/2261965f-112a-47e3-b7f9-cecb9dc4fe9f/Osteoporosis-prevention-diagnosis-and-management-in-postmenopausal-women-and-men-over-50-years-of-age.aspx
   Google Scholar
• Brieger D, Amerena J, Attia J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018;27(10):1209–1266.
   Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. Heart Rhythm. 2019 Jan 28;16:e66–e93.
   Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.
   Google Scholar
• López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.
   Google Scholar
• Xie X, Liu Y, Li J, et al. Fracture risks in patients with atrial fibrillation treated with different oral anticoagulants: a meta-analysis and systematic review. Age Ageing. 2022 Jan 6;51(1). DOI:10.1093/ageing/afab264
   Google Scholar
• Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46–56.
   Google Scholar